Clinical Potential of HER2 PET as a Predictive Biomarker to Guide the Use of Trastuzumab Deruxtecan in Breast Cancer Patients.

Romain-David Seban,Laurence Champion,Audrey Bellesoeur,Anne Vincent-Salomon,Francois-Clement Bidard

Journal of nuclear medicine : official publication, Society of Nuclear Medicine（2023）

引用 3|浏览11

暂无评分

摘要

TO THE EDITOR: We have read with great interest the results of the DESTINY-Breast04 trial, “Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer,” from Modi et al. and published in The New England Journal of Medicine ([1][1]). These impressive findings have also earned a

查看译文

关键词

trastuzumab deruxtecan,her2 pet,breast cancer patients,breast cancer,predictive biomarker

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要